S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
Senate rules referee weakens Dem drug plan in economic bill
Dems push Biden climate, health priorities toward Senate OK
China July exports rise, with trade surplus at record-high
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
Senate rules referee weakens Dem drug plan in economic bill
Dems push Biden climate, health priorities toward Senate OK
China July exports rise, with trade surplus at record-high
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
Senate rules referee weakens Dem drug plan in economic bill
Dems push Biden climate, health priorities toward Senate OK
China July exports rise, with trade surplus at record-high
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
Senate rules referee weakens Dem drug plan in economic bill
Dems push Biden climate, health priorities toward Senate OK
China July exports rise, with trade surplus at record-high
NYSE:ENZ

Enzo Biochem (ENZ) Stock Forecast, Price & News

$2.53
0.00 (0.00%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.48
$2.59
50-Day Range
$2.00
$2.62
52-Week Range
$1.98
$4.15
Volume
37,901 shs
Average Volume
52,967 shs
Market Capitalization
$123.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Enzo Biochem MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Enzo Biochem in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$426,524 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

949th out of 1,283 stocks

Medical Laboratories Industry

23rd out of 30 stocks

Enzo Biochem logo

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Wall Street Analysts Forecast Growth

ENZ has been the subject of several analyst reports. TheStreet cut shares of Enzo Biochem from a "c-" rating to a "d+" rating in a research report on Tuesday, May 17th. StockNews.com initiated coverage on shares of Enzo Biochem in a research report on Sunday, July 31st. They set a "hold" rating for the company.

Enzo Biochem Price Performance

Shares of ENZ Stock remained flat at $2.53 on Friday. The company had a trading volume of 37,901 shares, compared to its average volume of 52,967. The stock's 50 day moving average is $2.32 and its 200 day moving average is $2.73. The company has a market capitalization of $123.26 million, a PE ratio of -19.46 and a beta of 0.88. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.92 and a current ratio of 2.52. Enzo Biochem has a twelve month low of $1.98 and a twelve month high of $4.15.

Enzo Biochem (NYSE:ENZ - Get Rating) last posted its earnings results on Thursday, June 9th. The medical research company reported ($0.09) EPS for the quarter. The company had revenue of $26.22 million during the quarter. Enzo Biochem had a negative return on equity of 1.98% and a negative net margin of 5.88%.

Insider Activity at Enzo Biochem

In related news, Director Bradley Louis Radoff bought 120,000 shares of the firm's stock in a transaction on Tuesday, July 5th. The shares were purchased at an average price of $2.20 per share, with a total value of $264,000.00. Following the completion of the purchase, the director now owns 4,182,163 shares in the company, valued at approximately $9,200,758.60. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders purchased a total of 193,100 shares of company stock valued at $426,524 in the last quarter. Insiders own 17.40% of the company's stock.

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

StockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ)
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Enzo Biochem HPV Test Gets New York State Approval
Enzo Biochem names Kara Cannon as operating chief
See More Headlines

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Company Calendar

Last Earnings
6/09/2022
Today
8/07/2022
Next Earnings (Estimated)
10/11/2022
Fiscal Year End
7/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
451
Year Founded
N/A

Profitability

Net Income
$7.88 million
Pretax Margin
-5.88%

Debt

Sales & Book Value

Annual Sales
$117.73 million
Cash Flow
$0.26 per share
Book Value
$1.41 per share

Miscellaneous

Free Float
40,243,000
Market Cap
$123.26 million
Optionable
Optionable
Beta
0.88

Key Executives

  • Dr. Elazar Rabbani Ph.D. (Age 79)
    Co-Founder & Director
    Comp: $830.9k
  • Dr. Dieter Schapfel M.D. (Age 59)
    Chief Medical Director of Enzo Clinical Labs
    Comp: $404.03k
  • Mr. Hamid Erfanian (Age 52)
    CEO & Director
  • Mr. David A. Bench
    CFO, Sr. VP, Treasurer & Corp. Sec.
  • Ms. Kara Cannon (Age 53)
    Chief Operating Officer
  • Mr. Bruce A. Dey (Age 64)
    VP of Sales & Marketing - Enzo Clinical Labs













ENZ Stock - Frequently Asked Questions

How has Enzo Biochem's stock price performed in 2022?

Enzo Biochem's stock was trading at $3.21 on January 1st, 2022. Since then, ENZ stock has decreased by 21.2% and is now trading at $2.53.
View the best growth stocks for 2022 here
.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release its next quarterly earnings announcement on Tuesday, October 11th 2022.
View our earnings forecast for Enzo Biochem
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) posted its earnings results on Thursday, June, 9th. The medical research company reported ($0.09) EPS for the quarter. The medical research company earned $26.22 million during the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 1.98% and a negative net margin of 5.88%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by many different institutional and retail investors. Top institutional investors include Potomac Capital Management Inc. (1.15%), Potomac Capital Management Inc. (1.15%) and Assenagon Asset Management S.A. (0.04%). Company insiders that own Enzo Biochem stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, Harbert Management Corp, Kara Cannon and Peter J Iv Clemens.
View institutional ownership trends for Enzo Biochem
.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $2.53.

How much money does Enzo Biochem make?

Enzo Biochem (NYSE:ENZ) has a market capitalization of $123.26 million and generates $117.73 million in revenue each year. The medical research company earns $7.88 million in net income (profit) each year or ($0.13) on an earnings per share basis.

How many employees does Enzo Biochem have?

Enzo Biochem employs 451 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for Enzo Biochem is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.